Pay in 4 interest-free payments of $5.70 Learn more
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
The tirzepatide shelf life guide covers general storage principles in greater detail
By enhancing insulin sensitivity, GLP-1RAs may help lower inflammatory markers associated with these conditions
FDA Approved: Our product adheres to stringent safety and quality standards
BOOK YOUR COMPLIMENTARY CONSULTATION Get in touch
Two leading investigational therapies are attracting significant attention: MariTide (Maridebart Cafraglutide / AMG 133) Amgen Novel GLP-1 receptor agonist + GIP receptor antagonist Up to ~20% mean weight loss at 52 weeks in Phase 2 studies No weight-loss plateau observed at one year Currently advancing through the Phase 3 MARITIME program Potential for monthly or even less frequent administration PF-08653944 (Berobenatide) -Pfizer Ultra-long-acting GLP-1 receptor agonist Up to 12.3% placebo-adjusted weight loss at 28 weeks in Phase 2b Continued weight reduction after transition to monthly maintenance dosing No plateau observed at the 28-week analysis Designed to simplify long-term obesity management through monthly dosing Key Takeaway While MariTide currently leads in weight-loss efficacy, Pfizers Berobenatide highlights the potential of a streamlined, pure GLP-1 approach optimized for monthly maintenance and adherence
US$ 21.14
US$ 25.43
US$ 23.68
US$ 28.61
US$ 25.79
US$ 20.96
US$ 20.56
US$ 25.85
US$ 26.24
US$ 27.40
